Reality Check

Michael Simmons reflects on some of the economic highs and lows of 2025. Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcastsContact us: [email protected] Hosted on Acast. See acast.com/privacy for more information.

The Spectator’s Michael Simmons in conversation with Greg Jackson, CEO & Founder of Octopus Energy and non-executive member of the Cabinet Office BoardBecome a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcastsContact us: [email protected] Hosted on Acast. See acast.com/privacy for more information.

Junior doctors, now known as resident doctors, will strike from December 17 to 22, which Wes Streeting has said will 'wreck Christmas'. The doctors are demanding a 26 per cent salary rise over the next few years to make up for the erosion in their pay in real terms since 2008 – this is on top of a 28.9% increase they have had over the last three years. Michael Simmons takes a look at their claim over the erosion of their pay in real terms, explains why Wes Streeting is right to call them 'moaning minnies' and offers an alternative solution instead. Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcastsContact us: [email protected] Hosted on Acast. See acast.com/privacy for more information.

The Chancellor laid our her plans to scrap the two-child benefit cap in the Budget last week. Previously Rachel Reeves and the Prime Minister were against lifting the cap, but pressure from Reform and the back benches meant the government u-turned. The Resolution Foundation has backed this policy, arguing that it will help lift children out of poverty. But is this based on dodgy data? Michael Simmons investigates. Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcastsContact us: [email protected] Hosted on Acast. See acast.com/privacy for more information.

Lifestyle economist Christopher Snowdon joins Michael Simmons to explore how weight-loss drugs like Ozempic could reshape health, policy and the economy. From the WHO’s call for mass production to flawed obesity cost estimates, failing ‘nanny state’ interventions and the future of food companies, Snowden argues that these drugs are a genuine game-changer — and warns that much of current public health thinking is fast becoming obsolete.Become a Spectator subscriber today to access this podcast without adverts. Go to spectator.co.uk/adfree to find out more.For more Spectator podcasts, go to spectator.co.uk/podcastsContact us: [email protected] Hosted on Acast. See acast.com/privacy for more information.